Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average – Here’s Why

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.80 and traded as low as $2.44. Minerva Neurosciences shares last traded at $2.46, with a volume of 42,326 shares trading hands.

Wall Street Analysts Forecast Growth

NERV has been the subject of a number of research analyst reports. HC Wainwright dropped their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. StockNews.com initiated coverage on shares of Minerva Neurosciences in a research report on Friday. They set a “sell” rating for the company.

Minerva Neurosciences Price Performance

The business’s 50-day simple moving average is $2.68 and its two-hundred day simple moving average is $2.80.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). As a group, equities research analysts predict that Minerva Neurosciences, Inc. will post -2.26 earnings per share for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.